The proteolytic cleavage and subsequent inactivation of recombinant human factor Vlll (rhFVIII1 and human factor Vllla (rhFVllla) by recombinant human activated protein C (rAPC) was analyzed in the presence and absence of human protein S and human factor V (FV). Membrane-bound rhFVllla spontaneously looses most of its initial cofactor activity after 15 minutes of incubation at pH 7.4. The remaining activity can be eliminated after incubation with rAPC. Complete inactivation of the membrane-bound rhFVlll and rhFVllla by APC correlates with cleavage at ArgDS. The inactivation of rhFVlll and human plasma FV by rAPC were also compared. Under similar experimental conditions, complete inactivation of 0 I996 by The American Society of Hematology. 0006-497//96/8711-0039$3.00/0 rhFVIII. The effect of FV on the rhFVlll inactivation by APC is protein S-dependent, because FV alone has no effect on the inactivation rate of rhFVlll by APC. Western blotting using a monoclonal antibody that recognizes an epitope between amino acid residues 307 and 506 of human FV showed that FV was completely cleaved by APC at the beginning of the rhFVlll inactivation process. These data suggest that FV fragments derived from the 6 region of the procofactor after incubation of the membrane-bound procofactor with APC, but not intact single-chain FV, stimulate APC activity in the presence of protein S. rhFVIII, RI, and rhFVllla were not inactivated by GIuZO + Ala-substituted rAPC (rAPCyZoA), and membrane-bound factor Va was only partially inactivated. Our data suggest that (11 FV and FVa are the physiologically significant substrates for APC inactivation and (2) membrane-bound APC-treated FV is a cofactor for the APC inactivation of rhFVlll only in the presence of the intact form of protein S.
S and human factor V (FV). Membrane-bound rhFVllla spontaneously looses most of its initial cofactor activity after 15 minutes of incubation at pH 7.4. The remaining activity can be eliminated after incubation with rAPC. Complete inactivation of the membrane-bound rhFVlll and rhFVllla by APC correlates with cleavage at ArgDS. The inactivation of rhFVlll and human plasma FV by rAPC were also compared. Under similar experimental conditions, complete inactivation of membrane-bound FVlll (60 nmol/L) by rAPC (10 nmol/L) requires 4 hours of incubation, in contrast t o 5 minutes for FV (60 nmol/L). The presence of protein S (100 nmol/L) enhances rhFVlll inactivation by rAPC by 6.4-fold and FVa inactivation by twofold, whereas membrane-bound FV showed no protein S dependence during inactivation. The addition of human FV t o the APC/protein S inactivation mixture increases by approximately twofold the rate of inactivation of ACTOR V (FV) and factor VI11 (FVIII) are two high F molecular weight protein procofactors that circulate in plasma. Both can be activated by cy-thrombin into their active forms, FVa and FVIIIa, which are necessary for the efficient catalytic behavior of the prothrombinase and intrinsic tenase complexes, respectively.
FV circulates in plasma as a single-chain glycoprotein (molecular weight [M,] = 330,000). The procofactor consists of three A domains (Al, A2, and A3), two C domains (C1 and C2), and a connecting B domain.' Human FVIII shares a number of structural and functional similarities with FV'.' and circulates as a series of metal ion-dependent heterodimers with von Willebrand factor.4-' There is approximately 40% sequence identity between FV and FVIII.l,z a-Thrombin cleavages of FV at Arg70q and Arg's45 generate the FVa molecule.'.* Activation of FVIII by a-thrombin after cleavages at Arg"', Arg740, and Arg"" yields an heterotrimer composed by AI, A2, and A3-Cl-C2 domains.'.'" Upon a-
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rhFVIII. The effect of FV on the rhFVlll inactivation by APC is protein S-dependent, because FV alone has no effect on the inactivation rate of rhFVlll by APC. Western blotting using a monoclonal antibody that recognizes an epitope between amino acid residues 307 and 506 of human FV showed that FV was completely cleaved by APC at the beginning of the rhFVlll inactivation process. These data suggest that FV fragments derived from the 6 region of the procofactor after incubation of the membrane-bound procofactor with APC, but not intact single-chain FV, stimulate APC activity in the presence of protein S. rhFVIII, RI, and rhFVllla were not inactivated by GIuZO + Ala-substituted rAPC (rAPCyZoA), and membrane-bound factor Va was only partially inactivated. Our data suggest that (11 FV and FVa are the physiologically significant substrates for APC inactivation and (2) membrane-bound APC-treated FV is a cofactor for the APC inactivation of rhFVlll only in the presence of the intact form of protein S.
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thrombin activation, FVIIIa loses cofactor activity spontaneously after dissociation of the A2 subunit."."
Activated protein C (APC) is a vitamin K-dependent serine protease and a major anticoagulant in the blood clotting process. APC proteolytically inactivates coagulation factors V/Va and VIIWIIIa. Proteolytic cleavages by APC have been shown in bovine FV,13 bovine FVa,l4-lh human FV, and human FVa.".'* APC sequentially cleaves human FV at Arg30h, ArgSo6, Arg67', and Lys994. 18 Earlier data showed that FVIII is inactivated by APC at physiologic pH only in the presence of a membrane surface after single cleavage of the heavy-chain at Arg33h.9 More recently, it has been reported that APC inactivation of human FVIII and FVIIIa occurs after two sequential cleavages of the heavy chain at Arg5" followed by cleavage at Arg'36.'2 A probable cleavage site for APC at Arg740 has also been suggested for FVIII.'* APC exhibits optimal anticoagulant activity on FVIIWIIIa in the presence of another vitamin K-dependent protein, protein s.'' The significance of protein S as an anticoagulant can be viewed from the correlation of familial protein S deficiency and predisposition to recurrent venous thrombosis.24,25 Although there are many speculations about the function of protein S during blood ~lotting,'','~ the biologically relevant molecular mechanism by which protein S facilitates APC inactivation of the cofactors for prothrombinase and tenase is not yet fully understood. The only compelling data with respect to the role of protein S during clotting showed that protein S abrogates the ability of factor Xa (FXa) to protect FVa from cleavage by APC, without affecting the interaction of the two proteins within prothrombinase.**." It has also been reported that protein S increases the rate of inactivation of FVIII by approximately 1 0-fold.
Recently, APC-resistance has been shown in thrombotic individuals to correlate with an Arg506+Gln mutation in the FV molecule.",'2 Using purified FV from patients homozygous for the ArgSo'+Gln mutation, we have shown delayed inactivation of FVaR5"6Q by APC. ' For personal use only. on August 30, 2017 . by guest www.bloodjournal.org From factor V was also observed to correct the inherited resistance to APC when used at supraphysiologic concentration^.^^ It has been thus proposed that FV may act as a synergistic cofactor with protein S to stimulate APC activity. 35 Furthermore, it has been suggested that intact factor V may have anticoagulant properties acting as a cofactor for APC during factor VIIIa inactivation. However, these results have recently been the subject of intense contro~ersy.~~-'~ So far, there has been no systematic comparison of APCinactivation of FVNa and FVIIWIIIa to determine which of the two cofactor inactivations is of the greatest physiologic importance. One early study suggests that FVIII and FVa are equivalent substrates for APC,3* whereas a more recent study proposed that FVIIIa is the preferred substrate for APC." We compare here the inactivation rates of FVNa and FVIIWIIIa by APC in the presence of a membrane surface at physiologic pH. Our results show that, under these conditions, FVNa is the preferred substrate for APC. The present study also shows that membrane-bound APC-treated FV, not single-chain intact FV, at supraphysiologic concentrations, increases by approximately twofold the rate of inactivation of FVIII by APC only in the presence of protein S.
MATERIALS AND METHODS

Materials.
Wild-type recombinant human APC (rAPC) and rAPC with a GluZo+Ala substitution (rAPCyZoA) were prepared as described elsewhere." Human plasma protein S was a gift of Dr Paul Haley (Hematologic Technologies Inc, Essex Junction, VT) and is composed of a doublet of M, = 72,000/65,000 fragment (90% intact/lO% thrombin-cleaved, as suggested by sodium dodecyl sulfate polyacrylamide gel electrophoresis [SDS-PAGE]). Human FV, FVa, and a-thrombin were prepared as described elsewhere.w2
The cy-thrombin inhibitor hirudin was from Genentech (South San Francisco, CA). Recombinant human FVIII (rhFVIII) was a generous gift from Dr Roger Lundblad (Baxter Healthcare, Duarte, CA). Phospholipid vesicles composed of 75% L-palmitoyl-2-oleoylphosphatidylcholine (PC) and 25% L-palmitoyl-2-oleoylphosphatidylserine (PS) were prepared as described43 using PC (hen egg) and PS (bovine brain) from Sigma (St Louis, MO). Human factor V-deficient plasma was prepared by immunodepletion of normal plasma accordingly to a method described el~ewhere.~' Human FVIII-deficient plasma was purchased from George King Biomedical Inc (Overland Park, KS). Thromboplastin was purchased from Sigma.
Inactivation of FV and rhFVIII by APC. Human FV (60 nmoV L) or rhFVIII (60 nmol/L) were incubated with rAPC (0.6 or 10 n m o L as indicated in the figure legends) in the presence of 100 pmol/L PCPS in 20 mmol/L HEPES, 150 mmol/L NaCI, 5 mmoY L CaC12 (pH 7.4). Protein S (6 or 100 nmoVL) was present in the system as indicated. Hirudin (6 nmol/L) was added to inhibit potential contaminating thrombin in the APC preparations. At selected time intervals, FV or rhFVIII were assayed for activity by one-stage clotting assay.M At the same time intervals, another aliquot of the mixture was incubated with 2% SDS, 2% P-mercaptoethanol for subsequent SDS-PAGE analy~is.~'
The effect of FV on the inactivation of rhFVIII by rAPC was performed using procedures similar to those described above. The reaction mixture contained rhFVIII (60 nmol/L), 100 pmol/L PCPS in 20 mmol/L HEPES, 150 mmol/L NaCl, 5 mmoVL CaCl, (pH 7.4). rAPC (10 nmoVL) was added to the mixture to inactivate rhFVIII in the absence or presence of protein S (100 nmol/L) and different forms of human FV (100 nmol/L), as indicated in the figure legends. At the same time intervals, the activities of rhFVIII and FV were assayed, and samples were withdrawn for the Westem blot analysis of FV degradation using monoclonal antibody (~HFva,,~#6.~'
The effect of APC-cleaved FV was studied by preincubating FV Human rhFVIII (60 or 300 nmol/L, as indicated) was activated by a-thrombin (2 or I O nmoV L, as indicated) at 37°C for 2 minutes in the presence of 100 pmoU L PCPS in 20 mmol/L HEPES, 150 mmol/L NaCI, 5 mmol/L CaCI, (pH 7.4). Hirudin (100 nmoVL) was then added to stop the activation of rhFVIII. After 15 minutes and the stabilization of FVIIIa activity, rAPC ( I O nmol/L) was added. At selected time intervals, aliquots were assayed for remaining rhFVIIIa cofactor activity and also analyzed by SDS-PAGE analysis as described above.
Human FVa (60 nmol/L, purified or thrombin-activated FV) was inactivated by rAPC (0.6 nmoU L) in the absence and presence of protein S (6 or 100 nmoVL) using the conditions described above. The remaining FVa cofactor activity was assayed by clotting assay as described above.
Inactivation of rhFVIIIa by APC.
Inactivation of factor Vu by APC.
RESULTS
APC inactivation of rhFVIII.
Earlier data have shown that FVIII is inactivated after cleavage at Arg33h and generation of an M, = 40,000 fragment.9 The light chain of FVIII (amino acid residues 1690 through 2332) is not cleaved by APC. Closer examination of the data' shows the early appearance of intermediate fragments (M, -40,000 to 80,000) before the appearance of the M, = 40,000 fragment. Furthermore, several reports also indicate cleavage of the heavy chain by APC at another peptide bond(s) that correlates with inactivation.22. 30 rhFVIII (60 nmol/L) was incubated with rAPC (10 nmol/ L) and PCPS vesicles (100 pmol/L). At selected time intervals, aliquots of the mixture were assayed for activity ( Fig  IA) and analyzed by SDS-PAGE (Fig IB) . After 1 hour of incubation with rAPC, the membrane-bound procofactor retains approximately 50% of its initial potential cofactor activity, with only 10% remaining cofactor activity after 4 hours of incubation with rAPC ( Fig 1A) . The appearance of an M, = 40,000 fragment (amino acid residues 1 through 336) is delayed relative to the loss of activity, suggesting that transient initial fragments associated with loss in activity may not be seen during the initial inactivation process. Thus, the sensitivity of the staining method used in Fig 1B may not be sufficient enough to detect transient fragments previously reported by Fay et a12' (Fig IB, lanes 3 through 7, arrowheads). No cleavage of the M, = 80,000 light chain of rhFVIII by APC was observed. Our data are consistent with previous findings9322 and suggest that cleavages by APC at Arg336, Arg562, and probably Arg740 22 of the membrane-bound rhFVIII are responsible for inactivation.
It has been shown that FVIIIa rapidly looses its cofactor activity in solution after APC inactivation of rhFVIIIa. 
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dissociation of the A2 subunit." The K,, of the A2 subunit for the Alflight chain dimer is 0.27 pnol/L.J6 To verify if APC is responsible for inactivation of factor VIlIa or if inactivation of the cofactor primarily occurs because of the dissociation of the A2 subunit, rhFVIII at a concentration that is higher than that for subunit dissociation (300 nmol/ L) was activated by a-thrombin (10 nmol/L) in the presence of 200 pmol/L PCPS at pH 7.4. The reaction was stopped by hirudin (100 nmol/L). After 15 minutes of incubation, the reaction mixture was divided in two portions. One-half was incubated at 37°C. with no additions, and the cofactor show fragments deriving from APC cleavages of activity was monitored during the next 4 hours (Fig 2A, 0) . The other half was incubated with rAPC (10 nmol/L) at 37°C and the cofactor activity was monitored and is shown in Fig  2A (0) . At the same time intervals, aliquots of the rhFVIIIa/ rAPC mixture were also analyzed by SDS-PAGE (Fig 2B) . rhFVIIIa composed of the AIIA2flight chain trimer is rapidly inactivated (60% loss in cofactor activity after 5 minutes of incubation at 37°C) most likely as a consequence of the dissociation of the A2 subunit. The remaining activity (40%) is slowly eliminated by rAPC after cleavage of the A1 subunit at Arg'" (Fig 2) : Substantial amounts of the A2 subunit 
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remain after complete inactivation of rhFVIIIa and cleavage of the membrane-bound cofactor at Arg33" (Fig 28, lane 9) . The latter cleavage results in the disappearance of the A1 subunit of rhFVllla and generation of an M, = 40,000 fragment (Fig 2B, lane 9) . Our data suggest that rhFVllla is primarily inactivated by dissociation of the A2 subunit from the A lflight chain dimer. ( Fig 3) . Using similar experimental conditions, FV loses activity within 5 minutes of incubation with rAPC (10 nmol/ L; Fig 3A, A) , whereas 4 hours of incubation is necessary for complete rhFVIII inactivation (Fig 3B, 0) . At a lower APC concentration (0.6 nmol/L), FV (60 nmol/L) inactivation is achieved in 3 hours (Fig 3A, 0) . Protein S (6 or 100 nmol/L) has no effect on this reaction (Fig 3A, 0 and A) . In contrast, rhFVlIl inactivation by rAPC is enhanced by protein S (100 nmol/L) approximately 6.4-fold (Fig 3B, W) . SDS-PAGE analyses of the proteolytic fragments of Factor V and rhFVIII by APC show that inactivation of both FV and rhFVIII coincides with appearance of a fragment containing the NH2-terminal portion of the procofactors. The M, = 45,000 fraghent derived from FV after inactivation by APC represents the amino-terminal portion of the FV molecule after cleavage at Arg'"','' whereas the M, = 40,000 fragment derived from rhFVIII after inactivation by APC most likely results from cleavage at Arg316 (Fig l) . 9 These data indicate that inactivation of both membrane-bound procofactors involves a cleavage between the AI and A2 domains. These data also show that protein S is a cofactor for APC only for the inactivation of factor VIII.
The cofactor activity of FV on the APC-mediated inactivation of rhFVl11. Recent data have shown that FV enhances the rate of inactivation of FVIIIa by an APCIprotein S mixture." The data shown in Fig 4 demonstrate that FV increases the rate of inactivation of rhFVIII by approximately twofold in the presence of protein S (compare 0 and A). The enhancing effect was not observed in the absence of protein S (Fig  5, 0 ) . Furthermore, no interference with rhFVIII inactiva- The cofactor activity of membrane-bound APC-treated factor V. Because FV is the preferred substrate for APC, it is expected that, under the experimental conditions used above, FV would be rapidly cleaved by APC. Thus, to test the hypothesis that proteolytic fragments of FV can stimulate APC activity, membrane-bound FV was preincubated with rAPC and/or a-thrombin and the mixture was used as cofactor for rhFVIII inactivation in the presence or absence of protein S . APC-cleaved FV (Fig 6, A) or a-thrombincleaved FV (Fig 6, 0 ) can stimulate APC inactivation of rhFVIII in the presence of protein S . Unlike a-thrombincleaved FV, purified human FVa (lacking the B domain) has no cofactor activity on the APC-catalyzed inactivation of rhFVIII in the presence of protein S (Fig 5, 0) . These data strongly suggest that a portion of the B region of FV is involved in the FV cofactor function for rhFVIII inactivation. The possible mechanism could be that FV fragments facilitate the interaction of APC and protein S, hence enhancing APC activity.
To visualize the effect of FV on rhFVIII inactivation by APC, single-chain FV was incubated with rhFVIII in the presence of protein S. After the addition of rAPC, aliquots of the mixture were assayed separately for both FVIII and FV activity. Samples of the mixture were also analyzed by SDS-PAGE, transferred to nitrocellulose, and stained with a monoclonal antibody that recognizes an epitope located on an M, = 30,000 fragment generated by two cleavages of membrane-bound FV at residues Arg306 and Arg506.33 After 5 minutes of incubation of FV with rhFVIII, APC, and protein S , a complete loss in FV clotting activity is observed (Fig 7A) . Western blotting showed that FV was cleaved completely by APC within 5 minutes (Fig 7B) . Thus, membrane-bound APC-treated FV, not intact single-chain FV, is the cofactor for the APC/protein S mixture during inactivation of rhFVIII. Our data also show that, under our experimental conditions, there is no interference of FVIII with FV inactivation, because no significant difference in the inactivation rates of FV was observed in the absence (Fig 7A, 0 ) or presence (Fig 7A, 6 ) of rhFVIII. The data shown in Figs 4 through 7 show that one or more proteolytic fragments derived from membrane-bound FV serve as a cofactor for the APC-catalyzed inactivation of rhFVIII only in the presence of the intact form of protein S. Furthermore, our data show that FV is the preferred substrate for APC.
Comparative inactivation of the cofactors, FVa and rhFVllla. Figure 8A shows the inactivation of FVa (60 nmol/L) by rAPC (0.6 nmol/L) in the absence or presence of protein S . Protein S enhances FVa inactivation by rAPC in a dose-dependent manner, reaching a maximum of approximately twofold at 100 nmol/L (Fig SA, A) . Figure 8B shows that rhFVIIIa loses cofactor activity spontaneously at pH 7.4 after activation by a-thrombin (80% loss in activity after 15 minutes of incubation; Fig 8B, 0) . The 20% remaining cofactor activity is eliminated slowly by APC (10 nmolk) within 1 hour (Fig 8B, W) . These data are different from the data shown in Fig 2, in which only 60% cofactor activity was lost spontaneously at pH 7.4 and is most likely due to the fact that the experiment in Fig 8B uses a concentration that is less than the K,, for the association of the A2 subunit with the Al/light chain dimer, whereas the experiment in Fig 2 uses a concentration of rhFVIIIa greater than the K,, for the A2-AMight chain interaction.
Effect of recombinant APC with an amino acid substitution atposition 20 ( y +A, rAPCYzoA). rAPCy20A is impaired in membrane binding39 and, thus, has diminished inactivating proper tie^.^^ No change in the rhFVIIIa remaining cofactor activity was observed (Fig SB, 7) and no cleavage of the cofactor was noticed after 3 hours of incubation with rAPCy20A. rAPCyZoA also has no effect on FV and rhFVIII activity during 3 hours of incubation (Fig 9) . Protein S had no accelerating effect on rAPCy20A inactivation of FV and rhFVIII. Figure 10 shows that no proteolysis rhFVIII by rAPCy20A occurs in the absence (Fig 10A) or presence (Fig 10B) of protein S. These data demonstrate, as shown that both the substrate (FVNa and/or FVIIVVIIIa) and the enzyme (APC) must interact appropriately with the membrane surface for proper cleavage and inactivation.
DISCUSSION
Although FV and FVIII are similar in structure and function, the activation and inactivation processes are quite different. FV circulates as a single chain form and FVIII circulates as a population of metal ion-linked heterodimers. aThrombin cleaves FV to produce a two-chain molecule linked noncovalently in the presence of Ca2' with stable cofactor activity, whereas thrombin-cleaved FVIII (FVIIIa) loses activity spontaneously at pH 7.4, with a half-life of 2 minute^.'^.^^ FVIII is a poor substrate for APC, because relatively large amounts of APC are needed for complete i n a c t i v a t i~n .~~, '~.~~ In contrast, FV and FVa can be inactivated by catalytic amounts of APC. 18 The spontaneous loss of activity of FVIIIa after a-throm- 18) . The position of the M. = 30,000 fragment containing amino acid residues 307 through 506 is indicated at the right of (B), whereas the position of the molecular weight markers is indicated at left of IB).
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bin activation is well documented as being concentrationand pH-dependent.".".22.4X Complete inactivation of FVlIIa can be attributed to A2 subunit dissociation and APC proteolytic cleavage. From our experiments at pH 7.4, subunit dissociation accounts for approximately 60% to 80% loss of activity (depending on the starting concentration of FVIITa) and proteolytic cleavage for the remaining 20% to 40%.
Previous data suggested that inactivation of FVIlI is a result of cleavage at Arg5"* followed by cleavage at Arg33" and probably at Arg74n." Our data are in agreement with this finding, indicating that rhFVIII inactivation by APC results in the fragmentation of the heavy chain species of the cofactor. In contrast, the remaining cofactor activity after the spontaneous inactivation of rhFVIIIa at pH 7.4 can be eliminated after single cleavage by APC at Arg"6 (Fig 2) . Thus, it appears that cleavage at Arg"' by cy-thrombin plays the same role in rhFVIIIa inactivation by APC as cleavage by APC at Argsw plays in FVa for cleavage at Arg"."
It renders the FVllIa molecule more susceptible to cleavage at ArgJ3', which is the inactivating cleavage site.
Previous data showed that FVIII and FVa are equivalent substrates for APC and that increasing concentrations of However, these data are the subject of intense contr~versy?~,~' The effect of APC-treated FV on the protein S/APC-mediated inactivation of rhFVIII is small (with an increase in the rate of inactivation of twofold) but significant and is very sensitive to the quality of the reagents used.
Furthermore, the effect of FV in APC-inactivation of rhFVIII is dependent on the intact form of protein S . Thus, the need for good quality reagents and a certain range of concentration to see the effect may be the explanation of the controversy. We wish to point out that our experiments were performed in the absence of von Willebrand factor (vWF), which is the carrier protein for FVIII in plasma. Furthermore, vWF has been shown to protect FVIII from APC ina~tivation.4~ Thus, although the relevance of FV as a cofactor for inactivation of FVIII under physiologic conditions, ie, in the presence of vWF, remains to be established, the accelerating cofactor effect of FV on the APC/protein S-mediated inactivation of FVIIIa that was previously described3' is confirmed by our studies.
Overall, our data show that, whereas APC is required . For personal use only. on August 30, 2017 . by guest www.bloodjournal.org From for FVa inactivation, most of FVIIIa cofactor activity is spontaneously lost after dissociation of the A2 subunit. Hence, APC is not necessary for FVIIIa inactivation. These data are consistent with the concept that, after clot formation, APC will rapidly inactivate FVa, while concurrently, FVIIIa is spontaneously inactivated after dissociation of the A2 subunit. The proteolytic fragments resulting from APC inactivation of FVa will contribute, together with APC and protein S, to the fast and efficient inactivation of the remaining FVIIIa cofactor activity.
rAPCy'"" has been shown to have impaired membrane binding capabilities"' and, thus, reduced membrane-dependent activitie~.'~ rAPCY"'" cleaves FVa at Argsrm and partially inactivates the c~factor,'~ whereas activity assays and gel analyses indicated no proteolytic cleavage of FVIII or FVIIIa. It has also been shown that, in the absence of the light chain of the cofactors, cleavage of their respective heavy chain alone does not occur in the presence of APC and a membrane surface.'6~'7~sn Altogether, these data indicate that the proteolytic cleavages inactivating FVIII, FVIIIa, FV, and FVa require that both the substrates (FVIIINIIla and F V N a ) and the enzyme (APC) must be membrane associated.
To summarize, our results indicate that FV inactivation by APC is more rapid than FVIII and is independent of protein S. Our observations suggests that FV is the preferred substrate for APC and that inactivation of F V N a is of the greatest physiologic significance. However, protein S has a much greater ability to enhance FVIII inactivation by APC compared with FV. Additionally, the FV cofactor effect on the rhFV111 inactivation by APC is only expressed in the presence of protein S . Thus, our data may explain, in part, the physiologic importance of protein S in hemostasis as well as thrombophilia associated with protein S deficiency.
